Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
03/2005
03/31/2005WO2005027895A2 Thyroid hormone analogs and methods of use in angiogenesis
03/31/2005WO2005027890A1 Modafinil modified release pharmaceutical compositions
03/31/2005WO2005027889A1 Visceral pain dulling composition
03/31/2005WO2005027884A2 Stabilized ocular solutions
03/31/2005WO2005027881A2 Stable quinapril compositions
03/31/2005WO2005027880A1 Enteric soft gelatin capsule containing esomeprazole and method of preparation
03/31/2005WO2005027879A1 Coated tablets
03/31/2005WO2005027878A1 Delayed released dosage forms
03/31/2005WO2005027877A1 Antibiotic product, use and formulation thereof
03/31/2005WO2005027876A1 Pharmaceutical compositions of benzimidazole and processes for their preparation
03/31/2005WO2005027874A2 Solid or semi-solid therapeutic formulations
03/31/2005WO2005027873A2 Therapeutic aminoglycoside-containing hydrogel nanoparticles
03/31/2005WO2005027872A2 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
03/31/2005WO2005027871A2 Method for production of bioresorbable microparticles microparticles thus obtained and use thereof
03/31/2005WO2005027870A1 Buccal formulations of galanthamine and uses thereof
03/31/2005WO2005027867A1 Anhydrous topical formulation for polyphenols
03/31/2005WO2005027859A2 Patch
03/31/2005WO2005027852A2 Compositions of polyacids and polyethers and methods for their use in reducing pain
03/31/2005WO2005027843A2 Chronotherapeutic dosage forms
03/31/2005WO2005027832A2 Edta containing compositions and uses thereof
03/31/2005WO2005027822A2 Stabilized formulations of phosphatidylserine
03/31/2005WO2005027807A1 Pharmaceutical delivery system
03/31/2005WO2005027774A2 Method and apparatus for preventing allergies
03/31/2005WO2005027768A2 Hydrogel compositions with an erodible backing member
03/31/2005WO2005018702A3 Active agent delivery systems including a miscible polymer blend, medical devices, and methods
03/31/2005WO2005011636A3 Spray drying processes for forming solid amorphous dispersions of drugs and polymers
03/31/2005WO2005011600A3 Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same
03/31/2005WO2005009365A3 Antibiotic product, use and formulation thereof
03/31/2005WO2005007102A3 Phytochemicals for the treatment of mastalgia, endometriosis and hpv-related conditions including cervical dysplasia
03/31/2005WO2005002482A8 Transdermal hormone delivery system: compositions and methods
03/31/2005WO2004112696A3 Methods and compositions for delivery of catecholic butanes for treatment of diseases
03/31/2005WO2004103349A3 Breakable, controlled-release device comprising a preformed passage
03/31/2005WO2004103337B1 Improvements in adhesives and their applications
03/31/2005WO2004103299A8 Compositions and methods for the treatment of cns injuries
03/31/2005WO2004100883A3 Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same
03/31/2005WO2004096140A3 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
03/31/2005WO2004092394A3 Fluid planar lipid layer-based membrane-anchored ligand system with specific binding pair members and methods of use thereof
03/31/2005WO2004091578A3 Novel encochleation methods, cochleates and methods of use
03/31/2005WO2004091553A3 Film forming polymers, methods of use, and devices and applications thereof
03/31/2005WO2004080383A3 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
03/31/2005WO2004076369A3 Antimicrobial active borosilicate glass
03/31/2005WO2004069187A3 Drug formulation and delivery using crystalline methylated cyclodextrins
03/31/2005WO2004058305A3 Encapsulated cell for therapy
03/31/2005WO2004056314A3 Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
03/31/2005WO2004032900A8 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
03/31/2005WO2004006959A8 Liquid dosage compositions of stable nanoparticulate active agents
03/31/2005WO2003079992A3 Pulmonary delivery for levodopa
03/31/2005WO2003070909A3 Microparticles with adsorbed polypeptide-containing molecules
03/31/2005WO2002053102A3 Use of iv emulsions with different triglyceride composition, particle size and apolipoprotein e for targeted tissue delivery of hydrophobic compounds
03/31/2005US20050071003 Poly(vinyl alcohol) hydrogel
03/31/2005US20050070884 Osmotic pump with means for dissipating internal pressure
03/31/2005US20050070883 Devices and methods for controlled delivery from a drug delivery device
03/31/2005US20050070877 Therapy for mucous membrane secretions; respiratory system disorders; ostitis; cystic fibrosis; using interstitial compounds
03/31/2005US20050070721 PH-sensitive polymeric micelles for drug delivery
03/31/2005US20050070706 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070704 Clarified hydrocolloids of undiminished properties and method of producing same
03/31/2005US20050070703 Polysaccharide based network and method for the production thereof
03/31/2005US20050070613 deoxygenating aqueous solutions of catecholamines using inert gases, buffering, sterilization and storing in bottles; stabilization
03/31/2005US20050070611 Solubilized CoQ-10
03/31/2005US20050070610 Dermal compositions containing coenzyme q as the active ingredient
03/31/2005US20050070604 Vaginal cleanser; inhibit production of exotoxins from grampositive bacteria
03/31/2005US20050070536 Novel tablets and capsules and a process for its preparation
03/31/2005US20050070535 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070531 Using such as 2-[2-(3-Amino-piperidin-1-yl)4-oxo-4H-quinazolin-3-ylmethyl]-benzonitrile to treat cancer and/or autoimmune disorder
03/31/2005US20050070530 Dipeptidyl peptidase inhibitors
03/31/2005US20050070516 As-needed administration of an androgenic agent to enhance female desire and responsiveness
03/31/2005US20050070514 Administering phosphodiesterase 4 inhibitor in combination with beta agonist and an anti-inflammatory steroid
03/31/2005US20050070502 Orally administering a starch in granulated form having a reduced surface available for enzymatic degradation, which releases reducing sugars at a controlled rate; for nocturnal hypoglycemia in diabetes patients, endurance athletes
03/31/2005US20050070501 Water dispersible film
03/31/2005US20050070496 Semi-solid formulations for the oral administration of taxoids
03/31/2005US20050070491 Immunostimulatory nucleic acid molecules
03/31/2005US20050070487 Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
03/31/2005US20050070486 Microspherules containing a pleuromutilin derivative
03/31/2005US20050070481 By adding an antioxidant and/or a chelating agent in the same aqueous solution; reduced coenzyme Q10, vitamin C and ethylenediaminetetracetic acid for example
03/31/2005US20050070477 Lung surfactant polypeptide, and at least one inhibitor of a mediator of tissue destruction; for example protease inhibitors; treating inflammatory lung conditions such as asthma, chronic obstructive pulmonary disease
03/31/2005US20050070462 Contacting with cationic polymer
03/31/2005US20050070460 topically administering to the respiratory tract of a patient with infection, an immune response modifier compound in specific dosage to reduce infection by the agent
03/31/2005US20050069597 Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of alprostadil for the treatment of female sexual dysfunction
03/31/2005US20050069591 Injectable, oral, or topical sustained release pharmaceutical formulations
03/31/2005US20050069590 Stable suspensions for medicinal dosages
03/31/2005US20050069589 cross-linkable protein in the form of a solution or suspension; cross-linking agent solution includes an aldehyde and an amino acid containing species reactive with the aldehyde
03/31/2005US20050069587 Novel drug compositions and dosage forms of topiramate
03/31/2005US20050069586 Mixture with stabilization lubricant and excipients
03/31/2005US20050069585 Diphenhydramine tannate liquid and semi-solid compositions and methods of use
03/31/2005US20050069584 Diphenhydramine tannate solid dose compositions and methods of use
03/31/2005US20050069583 Solid, digestable mixture of alginate, (bi)carbonate and polyol; gastrointestinal disorders
03/31/2005US20050069582 Solubilized CoQ-10
03/31/2005US20050069581 Fish gelatin hard capsule and its preparation method
03/31/2005US20050069580 Compositions containing both sedative and non-sedative antihistamines and sleep aids
03/31/2005US20050069579 Non-gelatinous capsule film compositions and capsules using the same
03/31/2005US20050069578 Reconstitution medium for protein and peptide formulations
03/31/2005US20050069577 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
03/31/2005US20050069576 Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
03/31/2005US20050069575 Water soluble sheet composition
03/31/2005US20050069566 Foam carrier containing amphiphilic copolymeric gelling agent
03/31/2005US20050069533 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
03/31/2005US20050069499 Mixture of corticosteroid, propellant and carrier
03/31/2005US20050067726 Microcapsules having multiple shells and method for the preparation thereof
03/31/2005DE10341414A1 Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe For oral administration dosage form for sparingly soluble acidic and amphoteric agents
03/31/2005DE10341317A1 Mittel zur transdermalen Applikation Means for transdermal administration
1 ... 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 ... 2991